(Reuters) -The U.S. Food and Drug Administration said on Friday it has approved AstraZeneca's nasal spray flu vaccine for ...

It is not inevitable that H5N1 will develop into a pandemic -- if we act now. Unfortunately, instead of urgent action, we ...

A study investigating GSK’s investigational herpes simplex virus (HSV) vaccine candidate failed to meet its primary efficacy endpoint.

The potential of mRNA vaccines was established during the COVID-19 pandemic. Now, a new wave of candidates could soon hit the ...

Vaccines for the Fall and Winter 2024–2025 season are now available. Generally, experts recommend COVID-19 and flu vaccines ...

This health news summary discusses the mpox vaccine stockpiles in rich nations, Moderna's financial forecast, Morocco's first ...

"GSK reports positive interim data from mRNA influenza vaccine trial" was originally created and published by Clinical Trials ...

British drugmaker GSK on Thursday announced positive results from its mid-stage trial of its seasonal influenza vaccine programme using the messenger RNA (mRNA) technology, saying it would now ...

Thursday announced positive data from a phase II trial for its mRNA seasonal influenza vaccine programme. The study ...

DeepWell Digital Therapeutics received 510 (k) clearance from the FDA on its biofeedback software development kit for use in ...

GSK plc GSK announced that its therapeutic herpes simplex virus (HSV) vaccine candidate, GSK3943104, did not meet the primary ...

Also Read: GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech. Interim data suggest the vaccine candidates have an acceptable safety and ...